Home / Available CME / ARV Therapy Resistance
Credit Designation
ARV Therapy Resistance
About the Program
- Program Overview
- Target Audience
- Learning Objectives
- Course Directors
- Faculty
- Accreditation Statement
- Credit Designation
- Disclosure of Conflicts of Interest
- Disclosure of Unlabeled Use
- Insructions for Participation and Credit
- Disclaimer
- Request for Program Slides and Review
Program Overview
There are now more than 20 FDA-approved antiretroviral (ARV) drugs and 6 ARV classes. Since these therapies provide multiple treatment options for most patients, understanding resistance patterns that affect ARV efficacy and the potential contribution of drugs with low versus higher genetic resistance barriers is particularly relevant and important. In order for clinicians caring for HIV-positive patients to construct appropriate ARV regimens, it is critical that they understand the basic resistance issues that may affect the likelihood of successful, durable ARV therapy. This program will use an interactive, roundtable format, featuring 4 nationally known HIV thought leaders to evaluate and discuss important resistance issues. The roundtable will discuss and evaluate important ARV resistance issues and provide participants with education regarding all important clinical trials to date that examine ARV resistance issues and through a case-based format will allow participants to increase their expertise regarding and ability to recognize and manage ARV resistance.
This tuition-free program is for health care providers who treat HIV-positive patients and there are no prerequisites.
Back to Top
Target Audience
This activity has been designed to meet the educational need of physicians involved in the care of patients with HIV infection.
Back to Top
Learning Objectives
Upon completion of the program, participants should be more knowledgeable regarding and able to:
-
Discuss how ARV resistance occurs;
-
Explain the role resistance plays in ARV drug and regimen failure;
-
Apply the differing resistance characteristics and patterns of ARV drugs in order to achieve optimal virologic outcomes in individual patients;
-
Integrate information about resistance, resistance barriers and other relevant factors associated with ARV drug and regimen efficacy in a case-based discussion during the program.
Release Date: January 20, 2010
Expiration Date: January 20, 2011
Estimated time to complete the CME Program: 2 hours
Media: Internet
Back to Top
Course Directors
Calvin J. Cohen, MD, MS
Research Director, CRI New England
Clinical Instructor, Harvard Medical School
Boston, Massachusetts
Andrew Zolopa, MD
Associate Professor of Medicine
Division of Infectious Diseases
Stanford University School of Medicine
Palo Alto, California
Faculty
Roberto C. Arduino, MD
Professor of Medicine,
UT Director of Research,
Thomas Street Clinic
The University of Texas-Houston
Houston, Texas... Ian Frank, MD
Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania
John Bartlett, MD
Professor of Medicine,
Johns Hopkins School of Medicine
Baltimore, Maryland
Trevor Hawkins, MD
Associate Professor, University of New Mexico
Medical Director, Southwest CARE Center
Santa Fe, New Mexico
Rafael E. Campo, MD
Professor of Clinical Medicine
Division of Infectious Diseases
University of Miami School of Medicine
Jackson Memorial Hospital
Miami, Florida
Luther A. Virgil, Jr., MD
Chief Medical Officer,
National Minority Clinical Research Association
(NMCRA)
Fairfield, New Jersey
Eric Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, California
Peter J. Ruane, MD
Attending Staff,
Lightsource Medical
Section of Infectious Diseases,
Cedars-Sinai Medical Center
Los Angeles, California
Richard A. Elion , MD
Associate Professor of Clinical Medicine,
George Washington University Medical Center
Washington, DC
Paul Sax, MD
Clinical Director,
Brigham and Women’s Division
of Infectious Diseases and HIV Program
Associate Professor of Medicine,
Harvard Medical School
Boston, Massachusetts
Joseph Eron, MD
Professor
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Renslow Sherer, MD
Professor of Medicine,
Section of Infectious Diseases and
Global Health University of Chicago
Chicago, Illinois
Back to Top
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ViralEd, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary busniess interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or thier spouse/life partner have with commercial interests related to the content of these CME activities:
Dr. Andrew Zolopa:
- Contracted Research: Bristol-Myers Squibb; Gilead; Merck; Pfizer; Progenics; Schering-Plough; VIRxSYS
- Consulting Fees: Bristol-Myers Squibb; Gilead; Pfizer; Tibotec
- Speakers' Bureau: Tibotec
Dr. Calvin Cohen:
- Contrated Research: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Pfizer; Tibotec.
- Consulting Fees: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Pfizer; Tibotec.
- Speakers' Bureau: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Tibotec
Dr. Joe Eron:
- Contracted Research: GlaxoSmithKline; Panacos; Merck & Co.; TaiMed.
- Consulting Fees: Merck & Co.; Avexa; Bristol-Myers Squibb; GlaxoSmithKline; Tibotec; Virco Laboratories; Pfizer; Tobira; Chimerix; Myriad.
- Speakers' Bureau: Roche; Bristol-Myers Squibb; Tibotec (Not active since 1/1/09); Virco laboratories; Gilead Sciences (Not active).
Dr. Richard Elion:
- Contracted Research: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck & Co.; Rapid; Tibotec.
- Consulting Fees: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Tibotec.
- Speakers' Bureau: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Tibotec
Dr. Trevor Hawkins:
- Contracted Research: Gilead Sciences; GlaxoSmithKline; Pfizer; Salix.
- Consulting Fees: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Tibotec.
- Speakers' Bureau: Bristol-Myers Squibb; Gilead Sciences; Pfizer; Tibotec.
Dr. Roberto Arduino:
- Contracted Research: Advent/Kendle International Inc.; Pfizer
- Consulting Fees: GlaxoSmithKline; Gilead Sciences; Tibotec.
- Speakers' Bureau: Bristol-Myers Squibb; Gilead Sciences; Merck; Abbott; GlaxoSmithKline
Dr. Rafael Campo:
- Contracted Research: Gilead; Merck & Co.; Pfizer
- Consulting Fees: Abbott; Merck & Co.; Virco; Gilead Sciences; Tibotec.
- Speakers' Bureau: Bristol-Myers Squibb; Virco; Merck & Co.; Abbott
- Other: Wife is an employee of Merck & Co., in the asthma and diabetes divisions
Dr. John Bartlett:
- Contracted Research: Johnson & Johnson; Pfizer; Tibotec
- Speakers' Bureau: Abbott Laboratories
Dr. Luther Virgil:
- No real or apparent conflicts to disclose
Dr. Renslow Sherer:
- Contracted Research: Merck & Co.; Abbott Laboratories
- Consulting Fees: GlaxoSmithKline; Abbott Laboratories; Tibotec
- Speakers' Bureau: Gilead Sciences; Merck & Co.; Abbott Laboratories
Dr. Paul Sax:
- Contracted Research: Merck & Co.; Tibotec; GlaxoSmithKline
- Consulting Fees: GlaxoSmithKline; Gilead Sciences; Abbott Laboratories; Bristol-Myers Squibb; Tibotec; Pfizer
- Speakers' Bureau: Bristol-Myers Squibb
Dr. Peter Ruane:
- Contracted Research: Merck & Co.; Tibotec; Gilead; Progenics; Kakelsuken
- Consulting Fees: GlaxoSmithKline; Gilead Sciences; Merck & Co.; BI; Progenics; Tibotec; Pfizer
- Speakers' Bureau: Bristol-Myers Squibb; GlaxoSmithKline; Gilead Sciences; Merck & Co.; BI; Tibotec; Pfizer
Dr. Ian Frank:
- Consulting Fees: Pfizer; Abbott Laboratories; Bristol-Myers Squibb; Merck & Co.; Tibotec; Rapid
- Speakers' Bureau: Bristol-Myers Squibb; Gilead Sciences; Tibotec
Dr. Eric Daar:
- Contracted Research: Merck & Co.; Pfizer; Gilead; Abbott Laboratories; GlaxoSmithKline
- Consulting Fees: Schering Plough; Tibotec; Gilead; Pfizer
- Other: DSMB for Ardea
The planners and managers reported the following financial relationships or relationships to products or devices they or thier spouse/life partner have with commercial interests related to the content of these CME activities:
The following PIM planners and managers: Jan Hixon, RN, BSN, MS, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), ViralEd, LLC, and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ViralEd, LLC, and Merck & Co., Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions for Participation and Credit
There are no fees for participating and receiving credit for these activities. During the period, January 20, 2010 through January 20, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
Please complete the post-test online by going to www.cmeuniverstiy.com and follwing the instructions below:
- Click on "Find Post-Test/Evaluation by Course" on the navigation menu
- Enter project ID: 6833
- Complete post-test and evaluation to receive credit
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Request for Program Slides and Review
To request a copy of the program slides as well as further education on how to use the slides please Click Here to fill out a content request form.
Supported by an educational grant from Merck & Co., Inc.
Share this page:
